With $120m, HI-Bio Aims To Rapidly Prove Approach To Immune-Mediated Diseases

Phase Ib/IIa Trials To Read Out Next Year

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Human Immunology Biosciences (HI-Bio) launched with $120m and two candidates from MorphoSys, including the CD38 inhibitor felzartamab already in the clinic for immune-mediated kidney diseases.

Venture capital or financial support for startup and entrepreneur company
HI-Bio connected with new investor Jeito in its latest financing • Source: Shutterstock

Human Immunology Biosciences, Inc. (HI-Bio) made a splash over the summer as an unknown start-up that agreed to license two clinical-stage monoclonal antibodies from MorphoSys AG under a deal that could amount to as much as $1bn in milestone fees for the German firm. Now, HI-Bio has come out of stealth mode with $120m in initial funding and plans to rapidly validate its approach to immune-mediated diseases, first with the MorphoSys-discovered CD38 inhibitor felzartamab in two kidney diseases.

South San Francisco-based HI-Bio CEO Travis Murdoch is a physician-scientist with experience treating immune-mediated diseases – particularly, inflammatory bowel disease...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Sponsored By

Nancy Tests SPARC-931 Part 8

This is a short description. This is a short description.

spo

Akash test for clone

Test article to check the clone issue

More from Business

How A New Healthcare Dialogue Is Driving Market Access In Mexico

Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.